Novel Flowmeter Streamlines Urine Flow Screening
By HospiMedica International staff writers Posted on 16 Nov 2021 |
Image: The Oruflow fully automated, contactless, uroflowmetry device (Photo courtesy of Oruba)
An innovative self-operating device measures urine flow rate, providing important indicators for lower urinary tract symptoms (LUTS).
The Oruba (Ankara, Turkey) Oruflow is a fully automated, contactless, uroflowmetry device that requires no human intervention for function and sanitation. It has a built-in barcode scanner that registers the patient and collects all necessary information; textual, audio, and visual tutorials on using the device to ensure that the patient is adequately informed; and self-cleaning and sanitizing, preparing the device for use by the next patient in under a minute.
The internet-of-things (IoT)-supported uroflowmeter is designed to increase patient comfort and privacy. Oruflow starts the screening automatically, prepares a report while the patient is finishing up, prints it out for patient convenience, and also sends a digital version to the hospital information system (HIS). For clinics that do not use a barcode scanner, registration can be completed through Oruflow software, which can be used on any device with an internet connection; test results can also be examined on those devices.
“Oruba is a technology-focused startup with an interdisciplinary team of computer, electronics, mechanical and biomedical engineering, physics, industrial design, urology, and emergency care specialists,” stated the company. “Oruba is devoted to creating advanced medical devices that capture all bioinformation in human excreta. We are constantly working to develop innovations that can be highly scalable and have not been developed and in the world.”
Uroflowmetry is an essential tool to assess bladder and sphincter function. It requires the patient to urinate into a funnel-shaped device to measure amount of urine passed, urination speed (expressed in milliliters per second), and the length of time it takes to empty the whole bladder. Flow rates can help determine potential existence of diseases, such as benign prostate hyperplasia (BPH), bladder cancer, prostate cancer, neurogenic bladder dysfunction, and urinary blockage.
Related Links:
Oruba
The Oruba (Ankara, Turkey) Oruflow is a fully automated, contactless, uroflowmetry device that requires no human intervention for function and sanitation. It has a built-in barcode scanner that registers the patient and collects all necessary information; textual, audio, and visual tutorials on using the device to ensure that the patient is adequately informed; and self-cleaning and sanitizing, preparing the device for use by the next patient in under a minute.
The internet-of-things (IoT)-supported uroflowmeter is designed to increase patient comfort and privacy. Oruflow starts the screening automatically, prepares a report while the patient is finishing up, prints it out for patient convenience, and also sends a digital version to the hospital information system (HIS). For clinics that do not use a barcode scanner, registration can be completed through Oruflow software, which can be used on any device with an internet connection; test results can also be examined on those devices.
“Oruba is a technology-focused startup with an interdisciplinary team of computer, electronics, mechanical and biomedical engineering, physics, industrial design, urology, and emergency care specialists,” stated the company. “Oruba is devoted to creating advanced medical devices that capture all bioinformation in human excreta. We are constantly working to develop innovations that can be highly scalable and have not been developed and in the world.”
Uroflowmetry is an essential tool to assess bladder and sphincter function. It requires the patient to urinate into a funnel-shaped device to measure amount of urine passed, urination speed (expressed in milliliters per second), and the length of time it takes to empty the whole bladder. Flow rates can help determine potential existence of diseases, such as benign prostate hyperplasia (BPH), bladder cancer, prostate cancer, neurogenic bladder dysfunction, and urinary blockage.
Related Links:
Oruba
Latest Critical Care News
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
- AI Diagnostic Tool Guides Rapid Diagnosis and Prediction of Sepsis
- World's First AI-Powered Sepsis Alert System Detects Sepsis in One Minute
- Smartphone Magnetometer Uses Magnetized Hydrogel to Measure Biomarkers for Disease Diagnosis
- New Technology to Revolutionize Valvular Heart Disease Care